Jupiter Neurosciences (JUNS) said Monday that it signed an agreement with Catalent Pharma Solutions for the production of Jotrol softgel capsules for Jupiter's upcoming phase 2a clinical trial in Parkinson's disease.
Jotrol is Jupiter's oral formulation of resveratrol and under the deal, Catalent will manufacture clinical batches of Jotrol using a softgel formulation, according to the statement. No financial details were disclosed.
Jupiter said the production will include active and placebo batches for its planned Parkinson's study, which will evaluate Jotrol's safety, tolerability, and pharmacokinetics in patients with Parkinson's disease over a three-month period.
Shares of Jupiter Neurosciences were down more than 9% in recent Monday trading.
Price: 0.93, Change: -0.10, Percent Change: -9.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。